(0.23%) 5 143.25 points
(0.22%) 38 527 points
(0.31%) 17 900 points
(-0.52%) $83.41
(1.98%) $1.961
(-0.02%) $2 346.70
(0.28%) $27.61
(0.91%) $930.50
(-0.22%) $0.933
(-0.26%) $11.00
(-0.32%) $0.798
(1.06%) $92.85
@ $23.69
发出时间: 14 Feb 2024 @ 22:41
回报率: 44.58%
上一信号: Feb 13 - 22:30
上一信号:
回报率: 11.15 %
Live Chart Being Loaded With Signals
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases...
Stats | |
---|---|
今日成交量 | 90 155.00 |
平均成交量 | 452 214 |
市值 | 359.39M |
EPS | $0 ( 2024-03-12 ) |
下一个收益日期 | ( $-1.090 ) 2024-05-14 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -3.32 |
ATR14 | $0.107 (0.31%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-10 | Moran Sean F. | Buy | 1 787 | Common Stock |
2024-04-10 | Moran Sean F. | Sell | 1 787 | Employee Stock Option (right to buy) |
2024-03-08 | Cormorant Asset Management, Lp | Buy | 8 862 | Common Stock |
2024-03-08 | Cormorant Asset Management, Lp | Buy | 156 597 | Common Stock |
2024-03-08 | Cormorant Asset Management, Lp | Buy | 61 668 | Common Stock |
INSIDER POWER |
---|
99.57 |
Last 95 transactions |
Buy: 14 080 389 | Sell: 365 661 |
音量 相关性
Corbus Pharmaceuticals 相关性 - 货币/商品
Corbus Pharmaceuticals 财务报表
Annual | 2023 |
营收: | $0 |
毛利润: | $-641 000 (0.00 %) |
EPS: | $-10.31 |
FY | 2023 |
营收: | $0 |
毛利润: | $-641 000 (0.00 %) |
EPS: | $-10.31 |
FY | 2022 |
营收: | $0 |
毛利润: | $-1.49M (0.00 %) |
EPS: | $-13.39 |
FY | 2021 |
营收: | $881 705 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-0.370 |
Financial Reports:
No articles found.
Corbus Pharmaceuticals
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。